ZEALAND PHARMA/S (NASDAQ:ZEAL) Stock Rating Lowered by Zacks Investment Research
According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “
Several other research firms have also weighed in on ZEAL. TheStreet lowered shares of ZEALAND PHARMA/S from a c rating to a d+ rating in a research note on Friday, August 16th. Morgan Stanley upped their price objective on shares of ZEALAND PHARMA/S from $29.00 to $30.00 and gave the company an overweight rating in a research note on Monday, August 19th. Finally, Needham & Company LLC reiterated a buy rating and issued a $32.00 price objective (up previously from $29.00) on shares of ZEALAND PHARMA/S in a research note on Thursday, August 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $27.33.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.10). The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $7.50 million. As a group, analysts expect that ZEALAND PHARMA/S will post -2.22 EPS for the current year.
A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. Susquehanna International Group LLP purchased a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,348 shares of the company’s stock, valued at approximately $331,000. Hedge funds and other institutional investors own 9.38% of the company’s stock.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Featured Article: What is a CD ladder?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.